- Zomedica and Boehringer Ingelheim are collaborating to expand equine endocrine testing for PPID
- The agreement integrates TRUFORMA into Boehringer’s idPPID awareness and testing program
- Veterinarians will be able to perform rapid, point-of-care ACTH and insulin testing
- No-cost placement of TRUFORMA analyzers is expected to expand platform adoption
- The program includes reimbursement for diagnostic testing, supporting recurring revenue opportunities
Zomedica has announced a strategic collaboration with Boehringer Ingelheim Animal Health USA to expand access to equine endocrine diagnostic testing, with a focus on improving detection and management of pituitary pars intermedia dysfunction (PPID) in horses.
The collaboration integrates Zomedica’s TRUFORMA diagnostic platform into Boehringer Ingelheim’s idPPID awareness and testing program. The initiative enables veterinarians to conduct rapid, point-of-care endocrine testing using equine endogenous ACTH (eACTH) and insulin assays.
By enabling in-clinic testing, the program is designed to support earlier diagnosis and more timely treatment decisions for PPID, a common endocrine disorder in aging horses.
Under the agreement, Zomedica will promote the idPPID program across its TRUFORMA and PulseVet customer networks, while Boehringer Ingelheim will expand its program to include reimbursement for diagnostic testing performed using TRUFORMA, as well as laboratory-based testing through Cornell University.
The collaboration also includes no-cost placement of TRUFORMA analyzers in participating equine veterinary practices. This approach is expected to expand the installed base of the platform while enabling ongoing use of diagnostic cartridges, including additional assays such as cortisol and progesterone.
PPID, formerly known as equine Cushing’s disease, affects an estimated 20% to 25% of horses over the age of 15. The condition can impact metabolism, immune function, and overall health, making early detection and ongoing monitoring important components of care.
Zomedica said its TRUFORMA eACTH assay has demonstrated close agreement with reference laboratory results in comparative evaluations, supporting its use in both diagnosis and treatment monitoring.
The companies said the collaboration is intended to improve access to advanced diagnostic tools while supporting veterinarians in making faster, more informed clinical decisions. The model also supports recurring diagnostic revenue through continued use of assay cartridges following platform adoption.
The agreement reflects a broader strategy by Zomedica to expand utilization of its diagnostic platform through partnerships and integrated care programs, while leveraging Boehringer Ingelheim’s presence in the equine health market.
Information sourced from the company’s press release.
